{"id":243545,"date":"2026-09-11T11:33:45","date_gmt":"2026-09-11T06:03:45","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=243545"},"modified":"2026-09-11T11:33:45","modified_gmt":"2026-09-11T06:03:45","slug":"lincoln-pharmaceuticals-q2-results-fy27-preview-date-expectations","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/lincoln-pharmaceuticals-q2-results-fy27-preview-date-expectations\/","title":{"rendered":"Lincoln Pharmaceuticals Q2 Results FY27 Preview: Results Date, Expectations and the Numbers That Will Decide the September 2026 Quarter"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E79;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Lincoln Pharmaceuticals share price Rs 626.05 on 11 September 2026, down 1.02%. Q2 FY27 results date not confirmed. Q1 FY27 net profit Rs 36.00 crore. Q2 FY26 base a profit of Rs 20.00 crore.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E79;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">The Lincoln Pharmaceuticals Q2 results date for FY27 is not confirmed, and Lincoln Pharmaceuticals Ltd. had not filed a board meeting intimation with the NSE or BSE as of 11 September 2026. Indian listing rules require the September 2026 quarter results to be published within 45 days of the quarter end, an outer deadline of 14 November 2026. The quarter will be measured against a September 2025 base of Rs 163.00 crore in revenue and a profit of Rs 20.00 crore. This preview uses reported actuals only and carries no estimated revenue or profit figure for the coming quarter.<\/p>\n<\/p><\/div>\n<p>The Lincoln Pharmaceuticals Q2 results FY27 announcement is the next scheduled earnings event for <a href=\"https:\/\/univest.in\/stocks\/lincoln\/lincoln-pharmaceuticals-ltd-share-price-today\">Lincoln Pharmaceuticals Ltd.<\/a>, an Ahmedabad based maker of finished pharmaceutical formulations in tablet, capsule, injectable and liquid form, selling in India and exporting to markets across Africa, Latin America and Southeast Asia. The stock traded at Rs 626.05 on the NSE on 11 September 2026, down 1.02% from the previous close of Rs 632.50, about 20.8% below its 52-week high of Rs 790.00 and 39.1% above its 52-week low of Rs 450.10.<\/p>\n<p>What makes the Lincoln Pharmaceuticals Q2 results print worth watching is the base it faces. The September 2025 quarter delivered Rs 163.00 crore of revenue and a profit of Rs 20.00 crore, while the most recent quarter on record, Q1 FY27, produced Rs 177.00 crore and a profit of Rs 36.00 crore. Everything below is built from those reported figures rather than from any forecast.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=lincoln_q2_fy27\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/lincoln-pharmaceuticals-q2-results-fy27-preview-date-expectations\/#When_Is_the_Lincoln_Pharmaceuticals_Q2_Results_FY27_Date\" title=\"When Is the Lincoln Pharmaceuticals Q2 Results FY27 Date?\">When Is the Lincoln Pharmaceuticals Q2 Results FY27 Date?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/lincoln-pharmaceuticals-q2-results-fy27-preview-date-expectations\/#Lincoln_Pharmaceuticals_Q2_Results_Expectations_What_the_Market_Is_Actually_Tracking\" title=\"Lincoln Pharmaceuticals Q2 Results Expectations: What the Market Is Actually Tracking\">Lincoln Pharmaceuticals Q2 Results Expectations: What the Market Is Actually Tracking<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/lincoln-pharmaceuticals-q2-results-fy27-preview-date-expectations\/#Lincoln_Pharmaceuticals_Q2_Results_Preview_The_Q1_FY27_Actuals_It_Builds_On\" title=\"Lincoln Pharmaceuticals Q2 Results Preview: The Q1 FY27 Actuals It Builds On\">Lincoln Pharmaceuticals Q2 Results Preview: The Q1 FY27 Actuals It Builds On<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/lincoln-pharmaceuticals-q2-results-fy27-preview-date-expectations\/#Q2_FY26_Base_The_Comparison_Lincoln_Pharmaceuticals_Q2_Results_FY27_Must_Beat\" title=\"Q2 FY26 Base: The Comparison Lincoln Pharmaceuticals Q2 Results FY27 Must Beat\">Q2 FY26 Base: The Comparison Lincoln Pharmaceuticals Q2 Results FY27 Must Beat<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/lincoln-pharmaceuticals-q2-results-fy27-preview-date-expectations\/#Lincoln_Pharmaceuticals_Quarterly_Results_Trend_Over_the_Last_Four_Quarters\" title=\"Lincoln Pharmaceuticals Quarterly Results Trend Over the Last Four Quarters\">Lincoln Pharmaceuticals Quarterly Results Trend Over the Last Four Quarters<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/lincoln-pharmaceuticals-q2-results-fy27-preview-date-expectations\/#Key_Factors_That_Could_Shape_Lincoln_Pharmaceuticals_Q2_Results_FY27\" title=\"Key Factors That Could Shape Lincoln Pharmaceuticals Q2 Results FY27\">Key Factors That Could Shape Lincoln Pharmaceuticals Q2 Results FY27<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/lincoln-pharmaceuticals-q2-results-fy27-preview-date-expectations\/#Export_Registrations_Set_the_Market\" title=\"Export Registrations Set the Market\">Export Registrations Set the Market<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/lincoln-pharmaceuticals-q2-results-fy27-preview-date-expectations\/#The_March_Quarter_Has_a_Pattern\" title=\"The March Quarter Has a Pattern\">The March Quarter Has a Pattern<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/lincoln-pharmaceuticals-q2-results-fy27-preview-date-expectations\/#The_Balance_Sheet_Is_Effectively_Debt_Free\" title=\"The Balance Sheet Is Effectively Debt Free\">The Balance Sheet Is Effectively Debt Free<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/lincoln-pharmaceuticals-q2-results-fy27-preview-date-expectations\/#Lincoln_Pharmaceuticals_Q2_Results_FY27_Share_Price_and_Valuation_Going_Into_the_Print\" title=\"Lincoln Pharmaceuticals Q2 Results FY27: Share Price and Valuation Going Into the Print\">Lincoln Pharmaceuticals Q2 Results FY27: Share Price and Valuation Going Into the Print<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/lincoln-pharmaceuticals-q2-results-fy27-preview-date-expectations\/#What_Investors_Should_Watch_When_Lincoln_Pharmaceuticals_Q2_Results_Are_Announced\" title=\"What Investors Should Watch When Lincoln Pharmaceuticals Q2 Results Are Announced\">What Investors Should Watch When Lincoln Pharmaceuticals Q2 Results Are Announced<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/lincoln-pharmaceuticals-q2-results-fy27-preview-date-expectations\/#Conclusion_on_Lincoln_Pharmaceuticals_Q2_Results_FY27\" title=\"Conclusion on Lincoln Pharmaceuticals Q2 Results FY27\">Conclusion on Lincoln Pharmaceuticals Q2 Results FY27<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/lincoln-pharmaceuticals-q2-results-fy27-preview-date-expectations\/#FAQs_on_Lincoln_Pharmaceuticals_Q2_Results_FY27\" title=\"FAQs on Lincoln Pharmaceuticals Q2 Results FY27\">FAQs on Lincoln Pharmaceuticals Q2 Results FY27<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/lincoln-pharmaceuticals-q2-results-fy27-preview-date-expectations\/#What_is_the_Lincoln_Pharmaceuticals_Q2_results_date_for_FY27\" title=\"What is the Lincoln Pharmaceuticals Q2 results date for FY27?\">What is the Lincoln Pharmaceuticals Q2 results date for FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/lincoln-pharmaceuticals-q2-results-fy27-preview-date-expectations\/#What_quarter_do_the_Lincoln_Pharmaceuticals_Q2_results_2026_cover\" title=\"What quarter do the Lincoln Pharmaceuticals Q2 results 2026 cover?\">What quarter do the Lincoln Pharmaceuticals Q2 results 2026 cover?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/lincoln-pharmaceuticals-q2-results-fy27-preview-date-expectations\/#What_were_the_Lincoln_Pharmaceuticals_Q1_FY27_results\" title=\"What were the Lincoln Pharmaceuticals Q1 FY27 results?\">What were the Lincoln Pharmaceuticals Q1 FY27 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/lincoln-pharmaceuticals-q2-results-fy27-preview-date-expectations\/#What_were_Lincoln_Pharmaceuticals_Q2_FY26_results_in_the_September_2025_quarter\" title=\"What were Lincoln Pharmaceuticals Q2 FY26 results in the September 2025 quarter?\">What were Lincoln Pharmaceuticals Q2 FY26 results in the September 2025 quarter?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/lincoln-pharmaceuticals-q2-results-fy27-preview-date-expectations\/#What_are_the_main_Lincoln_Pharmaceuticals_Q2_results_expectations_this_quarter\" title=\"What are the main Lincoln Pharmaceuticals Q2 results expectations this quarter?\">What are the main Lincoln Pharmaceuticals Q2 results expectations this quarter?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/lincoln-pharmaceuticals-q2-results-fy27-preview-date-expectations\/#What_is_Lincoln_Pharmaceuticals_share_price_today_ahead_of_the_Q2_earnings\" title=\"What is Lincoln Pharmaceuticals share price today ahead of the Q2 earnings?\">What is Lincoln Pharmaceuticals share price today ahead of the Q2 earnings?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/lincoln-pharmaceuticals-q2-results-fy27-preview-date-expectations\/#Is_Lincoln_Pharmaceuticals_a_good_stock_to_buy_before_the_Q2_results\" title=\"Is Lincoln Pharmaceuticals a good stock to buy before the Q2 results?\">Is Lincoln Pharmaceuticals a good stock to buy before the Q2 results?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"When_Is_the_Lincoln_Pharmaceuticals_Q2_Results_FY27_Date\"><\/span><strong>When Is the Lincoln Pharmaceuticals Q2 Results FY27 Date?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Lincoln Pharmaceuticals Q2 results date for FY27 is not confirmed. As of 11 September 2026, Lincoln Pharmaceuticals Ltd. had not filed a board meeting intimation with the NSE or BSE for the September 2026 quarter, so any date circulating before that filing appears should be treated as unverified.<\/p>\n<p>What can be stated is the regulatory boundary. Listed companies in India must publish quarterly results within 45 days of the end of the quarter, which places the outer deadline for the September 2026 quarter at 14 November 2026. Companies also have to give the exchanges prior intimation of the board meeting that approves the results, so the Lincoln Pharmaceuticals Q2 results date becomes public through that filing rather than through any advance announcement.<\/p>\n<p>The Lincoln Pharmaceuticals Q2 results FY27 print covers 1 July 2026 to 30 September 2026. Small and mid-cap companies more often report in the second half of that window than in the first, so late October or early November is the range to watch for Lincoln Pharmaceuticals.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Lincoln_Pharmaceuticals_Q2_Results_Expectations_What_the_Market_Is_Actually_Tracking\"><\/span><strong>Lincoln Pharmaceuticals Q2 Results Expectations: What the Market Is Actually Tracking<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>No verified analyst estimate for the Lincoln Pharmaceuticals Q2 results FY27 quarter is in the public domain, so no revenue or profit figure should be assumed for Lincoln Pharmaceuticals. The Lincoln Pharmaceuticals Q2 results watchlist below is built from what the company has actually reported and disclosed.<\/p>\n<p>The first is revenue, which was Rs 163 crore in September 2025 against Rs 177 crore in Q1 FY27, a rise of about 9%. Sales have grown steadily from Rs 154 crore across the window with no break in the series.<\/p>\n<p>The second is the operating margin, which was 16% in September 2025 and 15% in Q1 FY27. The band is a narrow 13% to 16% throughout, so the operating line has been the stable part of this statement.<\/p>\n<p>The third is the other income line, which is doing most of the work. It swung from negative Rs 4 crore in March 2026 to positive Rs 24 crore in June 2026, a Rs 28 crore move, while operating profit changed only from Rs 25 crore to Rs 27 crore. That swing is what took net profit from Rs 12 crore to Rs 36 crore.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Check Lincoln Pharmaceuticals Ltd. Live Fundamentals on the Univest Screener<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Lincoln_Pharmaceuticals_Q2_Results_Preview_The_Q1_FY27_Actuals_It_Builds_On\"><\/span><strong>Lincoln Pharmaceuticals Q2 Results Preview: The Q1 FY27 Actuals It Builds On<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Lincoln Pharmaceuticals Ltd. reported revenue of Rs 177.00 crore in Q1 FY27, up 14.94% from Rs 154.00 crore in Q1 FY26, and a profit of Rs 36.00 crore at the net level, up 28.57% from Rs 28.00 crore in Q1 FY26. These are reported actuals, not estimates.<\/p>\n<p>Sequentially, revenue was down 5.35% over the March 2026 quarter figure of Rs 187.00 crore, and net profit was up 200.00% from Rs 12.00 crore in Q4 FY26. Operating margin stood at 15% in Q1 FY27 against 16% in the September 2025 quarter, which is the comparison the Lincoln Pharmaceuticals Q2 results print will be read against.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Q2_FY26_Base_The_Comparison_Lincoln_Pharmaceuticals_Q2_Results_FY27_Must_Beat\"><\/span><strong>Q2 FY26 Base: The Comparison Lincoln Pharmaceuticals Q2 Results FY27 Must Beat<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Lincoln Pharmaceuticals Ltd. reported revenue of Rs 163.00 crore and a profit of Rs 20.00 crore in Q2 FY26, the September 2025 quarter. That is the year-ago base against which the September 2026 numbers will be judged, and it is the single most useful figure in this Lincoln Pharmaceuticals Q2 results preview.<\/p>\n<p>Net profit in that base quarter was below the Rs 36.00 crore just reported for Q1 FY27, so the year-on-year comparison starts from a manageable level. Revenue of Rs 163.00 crore sits below the Rs 177.00 crore of the June 2026 quarter, which frames how much sequential movement the Lincoln Pharmaceuticals Q2 results print needs to show growth.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Lincoln_Pharmaceuticals_Quarterly_Results_Trend_Over_the_Last_Four_Quarters\"><\/span><strong>Lincoln Pharmaceuticals Quarterly Results Trend Over the Last Four Quarters<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<th>Quarter<\/th>\n<th>Revenue (Rs Cr)<\/th>\n<th>Net Profit (Rs Cr)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Q2 FY26 (Sep 2025)<\/td>\n<td>163.00<\/td>\n<td>20.00<\/td>\n<\/tr>\n<tr>\n<td>Q3 FY26 (Dec 2025)<\/td>\n<td>166.00<\/td>\n<td>29.00<\/td>\n<\/tr>\n<tr>\n<td>Q4 FY26 (Mar 2026)<\/td>\n<td>187.00<\/td>\n<td>12.00<\/td>\n<\/tr>\n<tr>\n<td>Q1 FY27 (Jun 2026)<\/td>\n<td>177.00<\/td>\n<td>36.00<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Figures in brackets denote negative numbers. All four quarters above are reported actuals taken from the company&#8217;s exchange filings, and they are the only basis this Lincoln Pharmaceuticals Q2 results preview uses.<\/p>\n<p>Revenue across those four quarters ranged from Rs 163.00 crore to Rs 187.00 crore, and net profit from Rs 12.00 crore to Rs 36.00 crore. That spread is the honest context for the Lincoln Pharmaceuticals Q2 results FY27 print, and it is why a single quarter should not be read as a trend on its own.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Factors_That_Could_Shape_Lincoln_Pharmaceuticals_Q2_Results_FY27\"><\/span><strong>Key Factors That Could Shape Lincoln Pharmaceuticals Q2 Results FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Lincoln Pharmaceuticals Q2 results outcome will turn on a small number of company-specific variables rather than on broad market conditions. The three below are the ones visible in what Lincoln Pharmaceuticals has already reported.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Export_Registrations_Set_the_Market\"><\/span><strong>Export Registrations Set the Market<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Selling formulations into Africa, Latin America and Southeast Asia requires country-by-country product registrations, so the addressable market grows with approvals rather than with demand. Tender-based institutional supply in those markets makes shipment timing lumpy.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"The_March_Quarter_Has_a_Pattern\"><\/span><strong>The March Quarter Has a Pattern<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Other income was negative Rs 4 crore in March 2026 and negative Rs 7 crore in March 2025, the only two negative readings in the displayed history. A recurring March-quarter adjustment on the investment book is the most likely reading.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"The_Balance_Sheet_Is_Effectively_Debt_Free\"><\/span><strong>The Balance Sheet Is Effectively Debt Free<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Borrowings of Rs 4 crore sit against reserves of Rs 738 crore, and interest rounds to zero in every quarter. The effective tax rate ranged from 18% to 31%, and the stock trades at a price to earnings ratio of 13.02 with return on equity of 12.3%.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Lincoln_Pharmaceuticals_Q2_Results_FY27_Share_Price_and_Valuation_Going_Into_the_Print\"><\/span><strong>Lincoln Pharmaceuticals Q2 Results FY27: Share Price and Valuation Going Into the Print<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Lincoln Pharmaceuticals share price today is Rs 626.05 on the NSE, down Rs 6.45 or 1.02% from the previous close of Rs 632.50 on 11 September 2026, ahead of the Lincoln Pharmaceuticals Q2 results announcement.<\/p>\n<table>\n<thead>\n<tr>\n<th>Metric<\/th>\n<th>Value (11 September 2026)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>NSE Symbol<\/td>\n<td>LINCOLN<\/td>\n<\/tr>\n<tr>\n<td>Current Market Price<\/td>\n<td>Rs 626.05<\/td>\n<\/tr>\n<tr>\n<td>52-Week High<\/td>\n<td>Rs 790.00<\/td>\n<\/tr>\n<tr>\n<td>52-Week Low<\/td>\n<td>Rs 450.10<\/td>\n<\/tr>\n<tr>\n<td>Market Capitalisation<\/td>\n<td>Rs 1,254 crore<\/td>\n<\/tr>\n<tr>\n<td>PE Ratio<\/td>\n<td>13.02<\/td>\n<\/tr>\n<tr>\n<td>PB Ratio<\/td>\n<td>1.66<\/td>\n<\/tr>\n<tr>\n<td>EPS (TTM)<\/td>\n<td>Rs 48.08<\/td>\n<\/tr>\n<tr>\n<td>Book Value per Share<\/td>\n<td>Rs 378.00<\/td>\n<\/tr>\n<tr>\n<td>Debt to Equity<\/td>\n<td>0.01<\/td>\n<\/tr>\n<tr>\n<td>Return on Equity<\/td>\n<td>12.3%<\/td>\n<\/tr>\n<tr>\n<td>50-Day Moving Average<\/td>\n<td>Rs 606.62<\/td>\n<\/tr>\n<tr>\n<td>200-Day Moving Average<\/td>\n<td>Rs 581.68<\/td>\n<\/tr>\n<tr>\n<td>RSI (14)<\/td>\n<td>59.08<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>The stock trades above both its 50-day average of Rs 606.62 and its 200-day average of Rs 581.68, with a 14-day RSI of 59.08. None of this is a view on where the shares go once the Lincoln Pharmaceuticals Q2 results are announced, and no price target is offered here.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Lincoln Pharmaceuticals Ltd. live price and quarterly earnings updates.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"What_Investors_Should_Watch_When_Lincoln_Pharmaceuticals_Q2_Results_Are_Announced\"><\/span><strong>What Investors Should Watch When Lincoln Pharmaceuticals Q2 Results Are Announced<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Four lines carry most of the information in a company of this size, and reading them in order keeps the Lincoln Pharmaceuticals Q2 results print in proportion.<\/p>\n<ol>\n<li>Revenue against the Rs 163.00 crore reported in the September 2025 base quarter<\/li>\n<li>Net profit against a profit of Rs 20.00 crore in that same quarter<\/li>\n<li>Operating margin against 15% in Q1 FY27<\/li>\n<li>Any exceptional item, provision or one-off gain disclosed alongside the numbers<\/li>\n<\/ol>\n<p>A one-off gain or provision can move the reported profit far more than operations do in a company this size, which is why the Lincoln Pharmaceuticals Q2 results announcement should be read together with the notes to the results rather than the headline alone.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion_on_Lincoln_Pharmaceuticals_Q2_Results_FY27\"><\/span><strong>Conclusion on Lincoln Pharmaceuticals Q2 Results FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Lincoln Pharmaceuticals Q2 results date is not confirmed, and 14 November 2026 is the statutory outer limit rather than an expected date. Lincoln Pharmaceuticals Ltd. will make the schedule public through a board meeting intimation to the exchanges, and until then the September 2026 quarter can only be framed by what has already been reported.<\/p>\n<p>On that basis the Lincoln Pharmaceuticals Q2 results FY27 print faces a base of Rs 163.00 crore in revenue and a profit of Rs 20.00 crore, with the most recent quarter having delivered Rs 177.00 crore and a profit of Rs 36.00 crore. No numerical estimate appears in this preview because no verified consensus figure exists for Lincoln Pharmaceuticals, and readers should treat any preview that supplies one with caution. Verify every figure against the company filing on release and consult a SEBI-registered advisor before acting on quarterly earnings.<\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/p><\/div>\n<h2><span class=\"ez-toc-section\" id=\"FAQs_on_Lincoln_Pharmaceuticals_Q2_Results_FY27\"><\/span><strong>FAQs on Lincoln Pharmaceuticals Q2 Results FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Lincoln_Pharmaceuticals_Q2_results_date_for_FY27\"><\/span><strong>What is the Lincoln Pharmaceuticals Q2 results date for FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The Lincoln Pharmaceuticals Q2 results date for FY27 is not confirmed. Lincoln Pharmaceuticals Ltd. had not filed a board meeting intimation with the NSE or BSE as of 11 September 2026. Indian listing rules require the September 2026 quarter results to be published by 14 November 2026 at the latest.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_quarter_do_the_Lincoln_Pharmaceuticals_Q2_results_2026_cover\"><\/span><strong>What quarter do the Lincoln Pharmaceuticals Q2 results 2026 cover?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The Lincoln Pharmaceuticals Q2 results FY27 cover 1 July 2026 to 30 September 2026, known as the September 2026 quarter. Lincoln Pharmaceuticals Ltd. reports revenue, operating profit and net profit for that period, and the Lincoln Pharmaceuticals Q2 results filing also carries the notes to the accounts.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_were_the_Lincoln_Pharmaceuticals_Q1_FY27_results\"><\/span><strong>What were the Lincoln Pharmaceuticals Q1 FY27 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Lincoln Pharmaceuticals Ltd. reported revenue of Rs 177.00 crore in Q1 FY27 and a profit of Rs 36.00 crore at the net level. Revenue was up 14.94% versus Q1 FY26 and net profit was up 28.57% from Rs 28.00 crore in Q1 FY26.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_were_Lincoln_Pharmaceuticals_Q2_FY26_results_in_the_September_2025_quarter\"><\/span><strong>What were Lincoln Pharmaceuticals Q2 FY26 results in the September 2025 quarter?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Lincoln Pharmaceuticals Ltd. reported revenue of Rs 163.00 crore and a profit of Rs 20.00 crore in Q2 FY26. Operating margin was 16%. Those figures form the base for the Lincoln Pharmaceuticals Q2 results FY27 comparison.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_main_Lincoln_Pharmaceuticals_Q2_results_expectations_this_quarter\"><\/span><strong>What are the main Lincoln Pharmaceuticals Q2 results expectations this quarter?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> No verified analyst estimate is publicly available. The Lincoln Pharmaceuticals Q2 results expectations centre on revenue against the Rs 163.00 crore base, net profit against a profit of Rs 20.00 crore, operating margin against 15% in Q1 FY27, and any exceptional item disclosed with the numbers.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_Lincoln_Pharmaceuticals_share_price_today_ahead_of_the_Q2_earnings\"><\/span><strong>What is Lincoln Pharmaceuticals share price today ahead of the Q2 earnings?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Lincoln Pharmaceuticals share price is Rs 626.05 on the NSE as of 11 September 2026, down 1.02% from Rs 632.50. The stock is about 20.8% below its 52-week high of Rs 790.00 and 39.1% above its 52-week low of Rs 450.10, at a market capitalisation of Rs 1,254 crore.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Lincoln_Pharmaceuticals_a_good_stock_to_buy_before_the_Q2_results\"><\/span><strong>Is Lincoln Pharmaceuticals a good stock to buy before the Q2 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> This article does not offer a buy, sell or hold recommendation on Lincoln Pharmaceuticals Ltd. The stock trades at a price-to-book ratio of 1.66 with a return on equity of 12.3%. Assess the reported numbers when they are released and consult a SEBI-registered financial advisor before making any decision.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What is the Lincoln Pharmaceuticals Q2 results date for FY27?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The Lincoln Pharmaceuticals Q2 results date for FY27 is not confirmed. Lincoln Pharmaceuticals Ltd. had not filed a board meeting intimation with the NSE or BSE as of 11 September 2026. Indian listing rules require the September 2026 quarter results to be published by 14 November 2026 at the latest.\"}},{\"@type\":\"Question\",\"name\":\"What quarter do the Lincoln Pharmaceuticals Q2 results 2026 cover?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The Lincoln Pharmaceuticals Q2 results FY27 cover 1 July 2026 to 30 September 2026, known as the September 2026 quarter. Lincoln Pharmaceuticals Ltd. reports revenue, operating profit and net profit for that period, and the Lincoln Pharmaceuticals Q2 results filing also carries the notes to the accounts.\"}},{\"@type\":\"Question\",\"name\":\"What were the Lincoln Pharmaceuticals Q1 FY27 results?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Lincoln Pharmaceuticals Ltd. reported revenue of Rs 177.00 crore in Q1 FY27 and a profit of Rs 36.00 crore at the net level. Revenue was up 14.94% versus Q1 FY26 and net profit was up 28.57% from Rs 28.00 crore in Q1 FY26.\"}},{\"@type\":\"Question\",\"name\":\"What were Lincoln Pharmaceuticals Q2 FY26 results in the September 2025 quarter?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Lincoln Pharmaceuticals Ltd. reported revenue of Rs 163.00 crore and a profit of Rs 20.00 crore in Q2 FY26. Operating margin was 16%. Those figures form the base for the Lincoln Pharmaceuticals Q2 results FY27 comparison.\"}},{\"@type\":\"Question\",\"name\":\"What are the main Lincoln Pharmaceuticals Q2 results expectations this quarter?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"No verified analyst estimate is publicly available. The Lincoln Pharmaceuticals Q2 results expectations centre on revenue against the Rs 163.00 crore base, net profit against a profit of Rs 20.00 crore, operating margin against 15% in Q1 FY27, and any exceptional item disclosed with the numbers.\"}},{\"@type\":\"Question\",\"name\":\"What is Lincoln Pharmaceuticals share price today ahead of the Q2 earnings?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Lincoln Pharmaceuticals share price is Rs 626.05 on the NSE as of 11 September 2026, down 1.02% from Rs 632.50. The stock is about 20.8% below its 52-week high of Rs 790.00 and 39.1% above its 52-week low of Rs 450.10, at a market capitalisation of Rs 1,254 crore.\"}},{\"@type\":\"Question\",\"name\":\"Is Lincoln Pharmaceuticals a good stock to buy before the Q2 results?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"This article does not offer a buy, sell or hold recommendation on Lincoln Pharmaceuticals Ltd. The stock trades at a price-to-book ratio of 1.66 with a return on equity of 12.3%. Assess the reported numbers when they are released and consult a SEBI-registered financial advisor before making any decision.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Lincoln Pharmaceuticals Q2 results FY27 date is not yet confirmed by the exchanges. Here is the September 2026 quarter watchlist for Lincoln Pharmaceuticals Ltd., built on actual Q1 FY27 and Q2 FY26 numbers with no invented estimates.<\/p>\n","protected":false},"author":29,"featured_media":243544,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5331],"tags":[],"class_list":["post-243545","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-https-univest-in-blogs-category-results"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["243544"],"rank_math_title":["Lincoln Pharmaceuticals Q2 FY27: Date and Outlook"],"rank_math_description":["Lincoln Pharmaceuticals Q2 results FY27 preview: results date status, key expectations, Q1 FY27 and Q2 FY26 actuals plus valuation before the September 2026 print."],"rank_math_focus_keyword":["Lincoln Pharmaceuticals Q2 results"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/09\/lincoln-pharmaceuticals-q2-results-fy27-preview-date-expectations.png","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/243545","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/29"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=243545"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/243545\/revisions"}],"predecessor-version":[{"id":243546,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/243545\/revisions\/243546"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/243544"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=243545"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=243545"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=243545"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}